Dr. Heather Jacene is Assistant Chief of Nuclear Medicine at Brigham Health, Clinical Director of Nuclear Medicine at Dana-Farber Cancer Institute, and an Associate Professor of Radiology at Harvard Medical School. She completed her residency and fellowship in Nuclear Medicine and PET/CT at Johns Hopkins University. Dr. Jacene has served as a Director on the American Board of Nuclear Medicine as well as on numerous committees within the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Her current positions include Associate Chair of Continuing Education for the Scientific Program Committee and Vice-Chair of the Quality Domain for SNMMI’s Value Initiative. Dr. Jacene’s research focuses on the use of FDG-PET/CT and other novel tracers for characterizing and monitoring response of cancer to therapy as well as the use of radionuclide therapy. She has over 70 peer-reviewed publications as well as many reviews and book chapters on these topics.
Disclosures: Dr. Jacene reports grants from Siemen Healthcare, grants from GTx, Inc, personal fees from Advanced Accelerator Applications, personal fees from Cambridge University Press, personal fees from Janssen Pharmaceuticals, personal fees from Memorial Sloan Kettering Cancer Center, personal fees from Cleveland Clinic, personal fees from Astellas Australia, personal fees from ANZUP, personal fees from ASCO, outside the submitted work